Study identifier:BY217/M2-124
ClinicalTrials.gov identifier:NCT00297102
EudraCT identifier:N/A
CTIS identifier:N/A
Effect of roflumilast on exacerbation rate in patients with COPD. The AURA Study
Chronic obstructive pulmonary disease (COPD)
Phase 3
No
Roflumilast, Placebo
All
1523
Interventional
40 Years +
Allocation: Randomized
Endpoint Classification: None
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Sept 2016 by AstraZeneca
AstraZeneca
-
The aim of the study is to investigate the effect of roflumilast on exacerbation rate and pulmonary function in patients with chronic obstructive pulmonary disease (COPD). Roflumilast will be administered orally once daily in the morning at one dose level. The study duration will last up to 56 weeks. The study will provide further data on safety and tolerability of roflumilast. For additional information (for US patients only) see www.COPDSTUDY.net or dial 866-788-2673 (toll free).
Location
Location
Fullerton, CA, United States, 92385
Location
Los Angeles, CA, United States, 90025
Location
Los Angeles, CA, United States, 90048
Location
Palmdale, CA, United States, 93551
Location
Rancho Mirage, CA, United States, 92270
Location
San Diego, CA, United States, 92120
Location
Bay Pines, FL, United States, 33708
Location
Miami, FL, United States, 33176
Arms | Assigned Interventions |
---|---|
Active Comparator: Roflumilast 500 mcg, once daily, oral administration in the morning | Drug: Roflumilast 500 mcg, once daily, oral administration in the morning |
Placebo Comparator: Placebo once daily | Drug: Placebo once daily |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.